Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Roche Holdings ADR RHHBY

Healthcare

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue... see more

Add To Watchlist

Recent & Breaking News (OTCQX:RHHBY)

Roche announces availability of the LightMix Modular Zika Virus Assay (CE) in markets accepting the CE mark

PR Newswire Europe Non Regulatory June 20, 2016

Has Cancer Research Become Cancerous? Same Cancer Strategy Targeted By 'Too Many Drugmakers,' Say Regulators

Benzinga.com June 13, 2016

Phase III Study Shows Genentech’s Actemra® (tocilizumab) Maintained Steroid-Free Remission in People With Giant Cell Arteritis (GCA)

Business Wire June 6, 2016

Genentech’s Cancer Immunotherapy TECENTRIQ™ (Atezolizumab) Shrank Tumors in People with Previously Untreated Advanced Bladder Cancer

Business Wire June 5, 2016

FDA Grants First Liquid Biopsy Approval to the Roche cobas® EGFR Mutation Test v2

PR Newswire June 1, 2016

Genentech’s Gazyva® Showed Superior Progression-Free Survival Compared to Rituxan® in People with Previously Untreated Follicular Lymphoma

Business Wire May 27, 2016

Roche Diabetes Care and Senseonics Announce Distribution Agreement for the Eversense® CGM System Introducing the First Implantable Long-term Glucose Sensor

PR Newswire Europe Non Regulatory May 25, 2016

Roche announces the first FDA-approved CMV test for use in hematopoietic stem cell transplant recipients

PR Newswire May 25, 2016

Phase III Study of Genentech’s Alecensa® (Alectinib) Showed Superior Efficacy Versus Crizotinib in Japanese People With a Specific Type of Lung Cancer

Business Wire May 18, 2016

Roche receives FDA Approval for novel PD-L1 biomarker assay

PR Newswire May 18, 2016

FDA Grants Genentech’s Cancer Immunotherapy TECENTRIQ™ (atezolizumab) Accelerated Approval for People with a Specific Type of Advanced Bladder Cancer

Business Wire May 18, 2016

Roche submits 510 (k) filing to FDA for Treponema pallidum assay to aid clinicians in the diagnosis of syphilis infection

PR Newswire May 18, 2016

Roche Announces Direct Sales of Kapa Biosystems NGS Products in Canada

Business Wire May 6, 2016

Genentech Highlights Personalized Medicines and Cancer Immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

Business Wire May 3, 2016

US insurance coverage for Harmony Prenatal Test from Roche expands to 200 million covered lives

PR Newswire May 2, 2016

Genentech to Present New Data at AAN Showing Superior Efficacy of Investigational Medicine Ocrelizumab Versus Comparators on Disease Activity and Progression in Two Forms of Multiple Sclerosis

Business Wire April 12, 2016

Genentech Announces FDA Grants Venclexta(TM) (venetoclax) Accelerated Approval for People With a Hard-to-Treat Type of Chronic Lymphocytic Leukemia

Business Wire April 11, 2016

Switzerland ETF Sort Of Stable, But Currency Is An Issue

Benzinga.com April 11, 2016

FDA Grants Priority Review for Genentech's Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer

Business Wire April 11, 2016

Roche to initiate testing for Zika virus at U.S. Blood Centres under FDA Investigational New Drug Application protocol

PR Newswire March 30, 2016